Anti-inflammatory humate compositions and methods of use thereof

Abstract

The invention relates to an anti-inflammatory composition containing humate, such as insoluble, granular, other insoluble, or soluble humate, particularly Menefee Humate®. The invention also includes other anti-inflammatory compositions containing humate and at least one additional anti-inflammatory agent such as indomethacin or another nonsteroidal anti-inflammatory drug. The invention includes a method of treating acute or chronic inflammation in an animal, including a human, by administering one of these compositions. A method of facilitating the therapeutic effect of a therapeutic drug in an animal by co-administering humate is also provided.

1. An anti-inflammatory composition comprising:
 MENEFEE HUMATE®; 
 at least one additional anti-inflammatory agent; and 
 a pharmaceutically acceptable carrier. 
 
     
     
       2. The composition of  claim 1 , wherein the humate is prehistoric humate. 
     
     
       3. The composition of  claim 2 , wherein the humate is derived from the Menefee Geological Formation in New Mexico. 
     
     
       4. The composition of  claim 1 , wherein the humate comprises at least 50% humic acids. 
     
     
       5. The composition of  claim 1 , wherein the composition is for oral or topical administration and the humate is insoluble, granular humate. 
     
     
       6. The composition of  claim 1 , wherein the composition is for injection administration and the humate is soluble. 
     
     
       7. The composition of  claim 1 , wherein the humate comprises between approximately 0.1% and 1.0% by weight of the total weight of the composition. 
     
     
       8. The composition of  claim 7 , wherein the humate comprises approximately 0.1–0.5% by weight of the total weight of the composition. 
     
     
       9. The composition of  claim 1 , wherein at least one additional anti-inflammatory agent is a nonsteroidal anti-inflammatory drug. 
     
     
       10. The composition of  claim 9 , wherein the nonsteroidal anti-inflammatory drug is an indole derivative. 
     
     
       11. The composition of  claim 10 , wherein the nonsteroidal anti-inflammatory drug is indomethacin. 
     
     
       12. A method of reducing inflammation in a tissue of an animal comprising:
 supplying a composition containing MENEFEE HUMATE® to the tissue through oral, topical or injection administration; and 
 supplying at least one additional anti-inflammatory agent to the tissue through oral, topical or injection administration. 
 
     
     
       13. The method of  claim 12 , wherein the humate is supplied orally and constitutes approximately 0.1 to 0.5% by weight of the total food consumed by the animal. 
     
     
       14. The method of  claim 12 , wherein at least one additional anti-inflammatory agent is supplied in the composition containing humate. 
     
     
       15. The method of  claim 12 , wherein the at least one additional anti-inflammatory agent is supplied in a separate composition from that containing humate. 
     
     
       16. The method of  claim 15 , wherein the at least one additional anti-inflammatory agent supplied in a separate composition is supplied approximately contemporaneously with the composition containing humate using the same type of administration. 
     
     
       17. The method of  claim 12 , wherein the dosage of the at least one additional anti-inflammatory agent is reduced as compared to an appropriate dosage in the absence of humate. 
     
     
       18. The method of  claim 13 , wherein the humate acts as a carrier to facilitate transport of the second anti-inflammatory agent to targets of activity of the second anti-inflammatory agent. 
     
     
       19. The method of  claim 12 , wherein the composition containing humate is supplied orally and wherein humate constitutes approximately 0.1–0.5% by total weight of an animal's food intake and the at least one additional anti-inflammatory composition is indomethacin administered in the amount of approximately 3 mg/kg animal. 
     
     
       20. The method of  claim 12 , wherein the animal is a human. 
     
     
       21. The method of  claim 12 , wherein the inflammation is acute. 
     
     
       22. The method of  claim 12 , wherein the inflammation is chronic. 
     
     
       23. The method of  claim 22 , wherein the inflammation is a result of arthritis.